New Drug Screening Tool for Cancer Research Comes to Market
by Michael Crowley | September 6, 2019
Breakthrough bioengineered, decellularized Wharton's Jelly matrix platform facilitates precision in vitro targeting of cancer stem cells (CSCs). The Sanatela™ Matrix is a revolutionary, natural 3-D biomaterial that gives researchers a tool to cultivate and study stem cells, including cancer stem cells. This matrix tissue opens new research opportunities for the development of individualized cancer treatments in the lab and for High-Throughput Drug Screening applications by pharmaceutical and biotechnology companies.